Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kaufen / Verkaufen

Top-Partner CFD-Broker

Plus500
  • Keine Kommissionen, enge Spreads
  • Hebel- und Long/Short-Trading, fortgeschrittene Analysetools, kostenlose Echtzeitkurse etc.
  • CFD-Trading auf Aktien, Indizes, Krypto, Rohstoffe und Devisen
Direkt zu Plus500 CFD service. Ihr Kapital unterliegt einem Risiko.

Premium-Partner

IG Bank
  • Ein weltweit führender CFD-Anbieter*, FINMA-reguliert
  • Über 17'000 Märkte: Indizes, Devisen, Rohstoffe, Aktien, Kryptowährungen, Optionen und mehr
  • Erweiterte Handelszeiten und Wochenendhandel
  • Schweizer Kundenserviceteam, mit Büros in Genf und Zürich
*Die IG Gruppe ist grösster Anbieter nach Umsatz (veröffentlichter Geschäftsbericht 2022)
Direkt zur IG Bank Verluste können Einlagen übersteigen.
Saxo Bank
  • Lizenzierte Schweizer Bank (FINMA)
  • Keine Depotgebühren bei aktivierter Wertpapierleihe
  • Aktien, ETFs, Optionen, FX, CFDs, Futures, Rohstoffe, Bonds, Mutual Funds - auf einer Plattform
  • Gratis Expertenanalysen und Trading-Signale
  • Saxo Deal: Rückerstattung der Courtagen bis CHF 200 während 90 Tagen
Direkt zur Saxo Bank
Werbung
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
19.12.2024 08:00:00

AGM Statement

DXS International
0.02 EUR 0.00%
Kaufen / Verkaufen

DXS INTERNATIONAL PLC

(AQSE: DXSP)

DXS AGM 2024 Statement

The Board of DXS International plc ("the Company” or "DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to publish an update on operations and pipeline progress ahead of its Annual General Meeting ("AGM") taking place today at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.

During the AGM, the Company's CEO, David Immelman, will provide an update on DXS’s progress. The Company made good progress in 2024 with both Aios SMART Referrals and ExpertCare, and achieved an NHS price increase.

Aios SMART Referrals

The existing Point of Care solution was replaced with Aios SMART Referrals, a new cloud based solution. NHS Electronic Referral System integration was completed, certified and NHS IMI accredited on the NHS G Cloud 14 Procurement Framework. SMART Referrals are now used for 10% of all referrals in England, an estimated 1.8 million per annum. Currently 22% of newly established Integrated Care Boards (ICBs) have some of their practices using Smart Referrals. These current paid for practices cover approx. 6.5m registered patients and there is the opportunity to convert the remaining GP practices to the Smart Referrals solution covering an additional 6.5m patients and to gain new market share in the remaining 78% of ICBs.

ExpertCare

ExpertCare is a unique Long Term Condition therapeutic management solution. Currently it has completed 75% or Phase 3 of 4 Phases of an Innovate UK grant with Health Innovate East, as announced in November 2023, with good results and York university is conducting an economic impact assessment. The first commercial sale was secured as announced on 29 October 2024.

Summary

The Company is looking to expand into at least one EU or other territory in 2025 and looks forward to updating the market in due course.

A Presentation that the CEO will deliver during the AGM is available for download from the Company's website at https://www.dxs-systems.co.uk/corporate-documents.php

We would like to thank our shareholders and other stakeholders for their continued support.

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

David Immelman

DXS International plc

www.dxs-systems.com


01252 719800
AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce



020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.


Nachrichten zu DXS International PLC Registered Shs

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
Keine Nachrichten verfügbar.

Analysen zu DXS International PLC Registered Shs

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 11’979.11 18.21 B66SCU
Short 12’150.00 13.19
Short 12’666.53 8.66 Y4SSMU
SMI-Kurs: 11’488.28 23.12.2024 17:31:04
Long 10’957.84 18.50 SSQMQU
Long 10’746.80 13.82 SSOMRU
Long 10’287.19 8.93 VSSM6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten